- Home
- HCKT vs XFOR Comparison
HCKT vs XFOR Comparison
Compare HCKT & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HCKT | XFOR |
|---|---|---|
| Founded | 1991 | 2014 |
| Country | United States | United States |
| Employees | N/A | 143 |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 392.0M | 407.5M |
| IPO Year | 1998 | N/A |
Fundamental Metrics
Financial Performance| Metric | HCKT | XFOR |
|---|---|---|
| Price | $13.31 | $4.24 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $17.00 | $9.00 |
| AVG Volume (30 Days) | 275.5K | ★ 459.5K |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | ★ 3.72% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.46 | N/A |
| Revenue | ★ $285,862,000.00 | N/A |
| Revenue This Year | $2.55 | N/A |
| Revenue Next Year | $5.07 | $80.31 |
| P/E Ratio | $28.07 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.19 | $0.17 |
| 52 Week High | $28.13 | $6.63 |
Technical Indicators
Market Signals| Indicator | HCKT | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 44.95 | 55.00 |
| Support Level | $12.76 | $3.01 |
| Resistance Level | $14.87 | $4.36 |
| Average True Range (ATR) | 0.52 | 0.35 |
| MACD | 0.10 | 0.01 |
| Stochastic Oscillator | 59.12 | 70.41 |
Price Performance
Historical ComparisonAbout HCKT Hackett Group Inc (The).
The Hackett Group Inc is an IP platform-based Generative Artificial Intelligence (Gen AI) strategic consulting and executive advisory digital transformation firm. The Hackett Group provides dedicated expertise in Gen AI-enabled enterprise transformation services across the front, mid and back office areas, including its highly recognized Oracle, SAP, OneStream and Coupa implementation offerings. It operates in three segments Oracle Solutions, SAP Solutions, and Global S&BT. It generates the majority of its revenue from the Global S&BT segment in the United States.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.